Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

2022128 citationsJournal Articlegold Open Access

Authors

Margherita Rimini · Istituti di Ricovero e Cura a Carattere Scientifico

Lorenza Rimassa · IRCCS Humanitas Research Hospital

Kazuomi Ueshima · Kindai University

Valentina Burgio · Vita-Salute San Raffaele University

S. Shigeo · Kurume University

Toshifumi Tada · Himeji Red Cross Hospital

Goki Suda

Abstract

The present analysis conducted on a large number of advanced non-viral HCC patients showed for the first time that treatment with lenvatinib is associated with a significant survival benefit compared to atezolizumab plus bevacizumab, in particular in patients with NAFLD/NASH-related HCC.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Hepatitis C virus research Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 7, Issue 6, pp. 100591-100591

DOI: 10.1016/j.esmoop.2022.100591

Field-Weighted Citation Impact: 16.62